Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer
August 12 2024 - 6:30AM
Atavistik Bio, a biotechnology company discovering the next
generation of precision allosteric therapeutics inspired by the
body’s natural regulators, today announced the appointment of Paul
Bruno, Ph.D., as Chief Business Officer. Dr. Bruno will lead
strategic execution of Atavistik Bio’s business and corporate
development efforts as the company advances its portfolio of
oncology-focused precision allosteric small molecule candidates
toward the clinic and leverages its platform to address a broad
spectrum of diseases.
“We’re thrilled to welcome Paul Bruno as Chief Business Officer
and strengthen our leadership team with this critical role,” said
Bryan Stuart, Chief Executive Officer at Atavistik Bio. “Paul’s
business and corporate development acumen, scientific aptitude,
collaborative approach, and authentic desire to help patients make
him an extraordinary addition to our team. As we approach key
upcoming milestones, both advancing our internal pipeline of
precision allosteric product candidates and expanding our
partnering initiatives to mine the expansive potential of our
platform, I look forward to Paul’s leadership and impact.”
“I’m excited to join the highly experienced Atavistik Bio team
and contribute to the company’s mission of delivering a new
generation of allosteric medicines to address serious unmet patient
needs,” said Dr. Bruno. “Allostery holds the key to targeting
numerous disease-causing proteins that, to date, have been
intractable. I’m extremely impressed with Atavistik Bio’s success
leveraging its proprietary platform to rapidly progress programs
towards the clinic and build a high-value oncology pipeline. I
believe Atavistik Bio is poised to transform the lives of countless
patients in the years ahead through a powerful combination of
internal and partnered programs.”
Dr. Bruno joins Atavistik Bio from Fulcrum Therapeutics, Inc.,
where he most recently served as Senior Vice President, Business
and Corporate Development. While at Fulcrum, Paul successfully
executed several licensing and financing transactions, including
the collaboration and license agreement with Sanofi in May 2024.
Prior to Fulcrum, Dr. Bruno was at ClearView Healthcare Partners, a
life sciences strategy firm that specializes in working with
biotech, pharma, and medtech companies. At ClearView, he worked
with clients on corporate strategy, portfolio management, pipeline
prioritization, and business development engagements.
Dr. Bruno received his Ph.D. in chemistry from the University of
Michigan and completed his postdoctoral fellowship at Boston
Children’s Hospital. He also holds a BS from Santa Clara
University, where he double majored in chemistry and public
health.
About Atavistik Bio
Atavistik Bio is a biotechnology company accelerating the
discovery and development of transformative precision allosteric
therapeutics to address serious unmet patient needs, with a focus
on oncology. Atavistik Bio is led by an experienced team of drug
hunters with a proven track record of developing marketed small
molecule therapies and supported by top-tier investors, including
The Column Group, Nextech Invest, and Lux Capital. To learn more,
visit us at atavistikbio.com and follow us on LinkedIn.
Media Contact:
Liz MeloneMelone Communications, LLCliz@melonecomm.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/924a451e-a31a-46f4-9993-257998a4398b